Anti-Transcriptional activator GLI3 Gli3 Antibody Picoband®

Overview

Anti-Transcriptional activator GLI3 Gli3 Antibody Picoband® is an antibody targeting GLI3. Common applications include WB, IHC, Flow Cytometry, ELISA. Key specifications include host: Rabbit; clonality: Polyclonal; isotype: Rabbit IgG; reactivity: Rat,Mouse,Human; observed MW: 33 kDa; calculated MW: 169863 MW.

Boster Bio Anti-Transcriptional activator GLI3 Gli3 Antibody catalog # PA1766. Tested in WB applications. This antibody reacts with Human, Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Key elements and design rationale

• Target: GLI3 — Transcriptional activator GLI3
• Antibody format: Host: Rabbit; Clonality: Polyclonal; Isotype: Rabbit IgG
• Species reactivity: Rat,Mouse,Human
• Molecular weight guidance: Observed: 33 kDa; Calculated: 169863 MW

Specificity note: No cross reactivity with other proteins.

Biological background

Protein function (datasheet): Has a dual function as a transcriptional activator and a repressor of the sonic hedgehog (Shh) pathway, and plays a role in limb development. The full-length GLI3 form (GLI3FL) after phosphorylation and nuclear translocation, acts as an activator (GLI3A) while GLI3R, its C-terminally truncated form, acts as a repressor. A proper balance between the GLI3 activator and the repressor GLI3R, rather than the repressor gradient itself or the activator/repressor ratio gradient, specifies limb digit number and identity. In concert with TRPS1, plays a role in regulating the size of the zone of distal chondrocytes, in restricting the zone of PTHLH expression in distal cells and in activating chondrocyte proliferation. Binds to the minimal GLI-consensus sequence 5'-GGGTGGTC-3'. .

Scientific background (datasheet): GLI3 (Gli-kruppel family member 3), also called ONCOGENE GLI3, encodes a member of the zinc finger gene family related to Kruppel, a gene that is known to regulate development in Drosophila. The GLI3 gene is expressed as an 8.5-kb mRNA in tissues such as testis, myometrium, placenta, and lung, and the protein product (relative molecular mass, 190,000) shows sequence-specific DNA binding. The GLI3 gene is mapped on 7p14.1. GLI3 is homologous to the Drosophila cubitus interruptus (ci) gene product (Ci), which regulates the Patched (pct), gooseberry (gsb), and decapentaplegic (dpp) genes. PKA-dependent processing of vertebrate GLI3 in developing limb generates a potent repressor in a manner antagonized by apparent long-range signaling from posteriorly localized Sonic hedgehog protein. The high relative abundance and potency of GLI3 repressor suggested specialization of GLI3 and its products for negative hedgehog pathway regulation.Coimmunoprecipitation and immunoblot studies showed that GLI3 protein is polyubiquitinated and that its processing depends on proteasome activity. The findings suggested that BTRC is required for GLI3 processing.

Cellular localization (datasheet): Nucleus. Cytoplasm. Cell projection, cilium. GLI3FL is localized predominantly in the cytoplasm while GLI3R resides mainly in the nucleus. Ciliary accumulation requires the presence of KIF7 and SMO. Translocation to the nucleus is promoted by interaction with ZIC1.

Tissue details (datasheet): Is expressed in a wide variety of normal adult tissues, including lung, colon, spleen, placenta, testis, and myometrium.

Sequence similarities (datasheet): Belongs to the GLI C2H2-type zinc-finger protein family.

Research relevance and current trends

• Commonly studied in contexts related to Domain Families,Epigenetics and Nuclear Signaling,Neural Signal Transduction,Neurology Process,Neuroscience,Nuclear,Signaling Pathways,Stem Cells,Transcription,Zinc Finger.
• Supports comparative expression analysis across conditions, genotypes, or treatments when paired with appropriate controls.
• Useful for confirming target presence and subcellular distribution using orthogonal readouts (e.g., microscopy vs. immunoblotting).

Common research applications

• Western blot (WB): Compare relative target abundance and apparent size/isoforms across samples; interpret bands in light of expected MW and potential PTMs.
• ELISA: Measure target abundance in compatible matrices using a standard-curve readout; ensure dilution linearity and appropriate controls.
• Immunohistochemistry (IHC): Assess tissue distribution and cell-type patterns; interpret staining with appropriate negative controls and antigen context.
• Flow cytometry: Quantify target-positive populations in single-cell suspensions; pair with viability and isotype/FMO controls conceptually.

Notes for experimental interpretation

• Consider isoforms, post-translational modifications, and processing that can shift apparent molecular weight or localization.
• Cross-reactivity (datasheet): No cross-reactivity with other proteins
• Use appropriate positive and negative controls (e.g., KO/KD, blocking peptide, or isotype controls) to support specificity interpretation.

As a polyclonal antibody, this reagent may recognize multiple epitopes on the target, which can improve detection robustness but may require careful specificity controls.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.